Biotechnology Jobs

• Zug, Switzerland
• On-site
• US$242,550 – US$404,250 pa
• Director · manages people

Senior physician leader providing medical oversight, safety evaluation and clinical data interpretation across lung cancer studies within a clinical programme team. Partners with the Senior Scientist and cross-functional groups on protocol design, regulatory interactions and external scientific engagement, while mentoring Medical Directors. Requires an on-site presence of at least two days a week at a GSK site.

• Waltham, United States
• Hybrid · 2–3 days in office
• US$222,750 – US$371,250 pa
• Director

Serves as the physician on oncology clinical programme teams for lung and head/neck cancers, leading medical monitoring, safety oversight and clinical data interpretation across Phase I–III studies. Partners with a Senior Scientist and cross-functional matrix teams on protocol development, regulatory interactions and investigator engagement, with on-site presence 2–3 days per week.

AI

• London
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development strategy for a hematology oncology portfolio, from first-in-human studies through registrational trials, regulatory approval and initial launch. Provides program oversight at governance forums, co-leads asset development with matrix partners, and line-manages Clinical Development Leads, Medical Directors and Clinical Scientists. Champions novel approaches such as AI/ML, innovative trial designs and real-world data.

AI/ML

• Upper Providence
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, approval and launch. Sets disease-area strategy, chairs governance forums and advisory boards, and line-manages clinical development leads within a global matrix. Distinct for its portfolio-level enterprise scope and hybrid US/UK/Swiss base.

AI/ML

• Baar Onyx
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, regulatory approval and initial launch. Chairs governance forums, co-leads matrix asset teams and line-manages clinical development leads, medical directors and clinical scientists. Distinct for its portfolio-level scope across early- and late-phase programs and its cross-functional connector role spanning research, translational medicine and commercial strategy.

AI/ML

• Stevenage
• Hybrid
• £119,250 – £198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late pre-candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• Waltham, United States
• Hybrid
• £188,100 – £313,500 pa
• Director

Leads model-informed drug development for oncology programs, defining and executing model-based strategies from late discovery through lifecycle management. Conducts population PK, exposure-response, simulation-based trial design and dose selection, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis. Presents to governance boards and regulators and works across matrix teams on small molecules, biologics and antibody drug conjugates.

NONMEM · R

• London
• Hybrid
• £119,250 – £198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within Oncology Translational Medicine's Clinical Pharmacology Modelling and Simulation group, working across small molecules, biologics and antibody drug conjugates.

NONMEM · R

• Belgium-Wavre
• Hybrid
• €119,250 – €198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis to small molecules, biologics and antibody drug conjugates. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• USA - Pennsylvania - Upper Providence
• Hybrid
• US$188,100 – US$313,500 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• Durham Blackwell Street
• Hybrid
• US$188,100 – US$313,500 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within a matrixed Clinical Pharmacology Modelling and Simulation group working across small molecules, biologics and antibody drug conjugates.

NONMEM · R

• Waltham, United States
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with cross-functional partners in digital medicine, translational imaging and systems modelling. Based in the newly established Clinical Pharmacology and Quantitative Medicine organisation.

MIDD · QSP · AI/ML

• London
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with digital medicine, imaging, modelling and data science partners. Reports into the Respiratory, Immunology & Inflammation Research Unit.

AI/ML · Digital Medicine · Translational Imaging +3

• Stevenage
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with digital medicine, translational imaging and modelling specialists. Based in Stevenage with a planned relocation to Cambridge, UK by early 2029.

MIDD · QSP · AI/ML

• Durham, United States
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and partners with digital medicine, translational imaging, biostatistics and AI/ML teams. Reports into the Respiratory, Immunology & Inflammation Research Unit within the new Clinical Pharmacology and Quantitative Medicine organisation.

MIDD · QSP · AI/ML